Netherlands· NL-67440582b0f1
Nimotop 0,2 mg/ml, oplossing voor infusie
A nimodipine product containing nimodipine, registered in Netherlands by Laboratoire X.O.. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Nimodipine is registered in 14 of 19 countries.
Countries holding a registration under ATC C08CA06 (nimodipine), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Nimodipine · ATC C08CA06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nimodipine costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), the median price runs from $5.28 in France to $7.99 in Switzerland — a ×1.5 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nimodipine · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$7.99
- FR France$5.28
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- NIMODIPINE
- Manufacturer
- Laboratoire X.O.
- Country
- Netherlands (NL)
- ATC code
- C08CA06
- ATC class
- Nimodipine
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id12061
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
202 interactions on record for nimodipine.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nimodipine · interactions on record
202 records
- 15 severe
- 164 moderate
- 1 minor
- 20 info
Most severe, free to view
- DolasetronA04AA04severe
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nimodipine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandNimodipine AltanInPharm Sp. z o.o.
- SwedenNimotop 0,2 mg/ml Infusionsvätska, lösningEbb Medical AB
- FinlandNimotopLaboratoire X.O
- SpainNIMODIPINO ALTAN 0,2 MG/ML SOLUCION PARA PERFUSION EFGAltan Pharmaceuticals Sa
- CzechiaDILCERENZentiva, k.s., Praha
- BelgiumNimotop 10 mg/50 mlLaboratoire X.O
- NorwayNimotopLaboratoire X.O.
- SwitzerlandNimotop 10 mg/50 ml, InfusionslösungFuture Health Pharma GmbH
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Nimotop
- Belgium · Nimotop
- Bulgaria · Нимотоп S
- Cyprus · Nemotan
- Czechia · Dilceren, Nimotop S
- Germany · Nimodipin Carinopharm, Nimodipin Ethypharm
- Denmark · Nimotop
- Estonia · Nimotop
- Spain · Brainal, Nimodipino Altan
- Finland · Nimotop
- France · Nimodipine Altan, Nimotop
- United Kingdom (Northern Ireland) · Nimotop
- Greece · Befimat, Curban
- Croatia · Nimotop S
- Ireland · Nimotop
- Italy · Iskidrop, Nimobrain
- Luxembourg · Nimotop
- Latvia · Nimotop
- Norway · Nimotop
- Poland · Nimotop S
- Portugal · Brainox, Modina
- Romania · Nimotop
- Sweden · Nimotop
- Slovenia · Nimodipin Bayer, Nimodipin Laboratoire X.O
- Slovakia · Dilceren Pro Infusione, Nemotan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/233e8885-79c8-4aed-96ad-e17e47150d7e GET /v1/drugs/233e8885-79c8-4aed-96ad-e17e47150d7e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor infusie",
"route": null,
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h12061_smpc.pdf",
"strength": null,
"atc_label": "Nimodipine",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg12061",
"excipients": [
"CITROENZUUR 0-WATER (E 330)",
"ETHANOL 96 %",
"MACROGOL 400",
"STIKSTOF (HEAD SPACE) (E 941)",
"TRINATRIUMCITRAAT 2-WATER (E 331)",
"WATER VOOR INJECTIE"
],
"substances": [
"NIMODIPINE"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h12061.pdf",
"authorised_at": "1989/06/06",
"procedure_number": null,
"dispensing_status": "Uitsluitend recept",
"registration_number": "12061",
"additional_monitoring": "N"
}See everything about nimodipine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.